HEM Pharma Inc
KOSDAQ:376270
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
HEM Pharma Inc
KOSDAQ:376270
|
KR |
|
S
|
Saltbae Capital Corp
CNSX:CUBE
|
CA |
|
Being Holdings Co Ltd
F:SO0
|
JP |
|
Noble Iron Inc
XTSX:NIR
|
CA |
|
P
|
Pacific American Holdings Ltd
ASX:PAK
|
AU |
|
C
|
Cresud SACIF y A
BCBA:CRES
|
AR |
|
K
|
KWG Resources Inc
CNSX:CACR
|
CA |
|
Sagalio Energy Ltd
ASX:SAN
|
HK |
|
Hemostemix Inc
XTSX:HEM
|
CA |
|
A
|
Altri SGPS SA
XMUN:ACJ
|
PT |
|
B
|
BSA Logistics Indonesia Tbk PT
IDX:WBSA
|
ID |
Bankruptcy Probability
HEM Pharma Inc's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Financial Position
| Mar 31, 2026 | 12.5B |
| Dec 31, 2025 | 5.3B |
| Sep 30, 2025 | 5.3B |
| Jun 30, 2025 | 10.6B |
| Mar 31, 2026 | 1.5B |
| Dec 31, 2025 | 273.5m |
| Sep 30, 2025 | 273.5m |
| Jun 30, 2025 | 62.2m |
| Mar 31, 2026 | 12.5B |
| Dec 31, 2025 | 11.9B |
| Sep 30, 2025 | 11.9B |
| Jun 30, 2025 | 10.5B |
Solvency Ratios
Solvency Ratios Comparison
HEM Pharma Inc Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KR |
H
|
HEM Pharma Inc
KOSDAQ:376270
|
325.4B KRW |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| JP |
|
Takara Bio Inc
TSE:4974
|
120.4T JPY |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
443.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
226.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
130.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
45.7B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
65.8B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
HEM Pharma Inc's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, HEM Pharma Inc has total debt of 12.5B KRW. This includes both short-term (7.4B KRW) and long-term (5.1B KRW) debt.
You can find a full breakdown on its Balance Sheet.
